Express News | VYNE Therapeutics Doses First Volunteers In Phase 1a Trial Of VYN202; Oral BET Inhibitor Targeting Immuno-Inflammatory Diseases; Top-Line Data Expected In H2 2024
Express News | Vyne Therapeutics Inc: Top-Line Data Expected in 2H'24
Express News | Vyne Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel Bd2-Selective Bet Inhibitor Vyn202
LifeSci Capital Maintains VYNE Therapeutics(VYNE.US) With Buy Rating, Maintains Target Price $6
LifeSci Capital analyst Rami Katkhuda maintains $VYNE Therapeutics(VYNE.US)$ with a buy rating, and maintains the target price at $6.According to TipRanks data, the analyst has a success rate of 38.1%
Top Premarket Gainers
Geron (GERN) shares were up 28% premarket Friday after the company said it received US Food and Drug Administration approval for its drug Rytelo as a treatment for adult patients with lower-risk myelo
H.C. Wainwright Maintains VYNE Therapeutics(VYNE.US) With Buy Rating, Maintains Target Price $5.75
H.C. Wainwright analyst Joseph Pantginis maintains $VYNE Therapeutics(VYNE.US)$ with a buy rating, and maintains the target price at $5.75.According to TipRanks data, the analyst has a success rate of
Express News | VYNE Therapeutics Doses First Subject In Phase 2b Vitiligo Trial Of VYN201
Express News | Vyne Therapeutics Announces Dosing of First Subject in Phase 2B Vitiligo Trial of Novel Bet Inhibitor Vyn201
Buy Rating Affirmed for VYNE Therapeutics on Promising Clinical Advancements and Strategic Pipeline Progression
Analysts' Top Healthcare Picks: VYNE Therapeutics (VYNE), TriSalus Life Sciences (TLSI)
VYNE Therapeutics | 10-Q: Quarterly report
Buy Rating for VYNE Therapeutics on Strong Financial Footing and Promising Clinical Pipeline
VYNE Therapeutics Q1 EPS $(0.15) Beats $(0.24) Estimate, Sales $98.00K Miss $100.00K Estimate
VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.24) by 37.5 percent. This is a 89.86 percent increase over losses of $(1
Express News | Vyne Reports First Quarter 2024 Financial Results and Provides Business Update
Express News | Vyne Therapeutics Q1 Net Income USD -6.249 Million
Express News | Vyne Therapeutics Q1 Revenue USD 98 Thousand
Press Release: VYNE Reports First Quarter 2024 Financial Results and Provides Business Update
VYNE Reports First Quarter 2024 Financial Results and Provides Business Update -- Design of Phase 2b trial for VYN201 in nonsegmental vitiligo finalized and on track to begin this quarter
Vyne Therapeutics 1Q Loss/Shr 15c >VYNE
Vyne Therapeutics 1Q Loss/Shr 15c >VYNE
Express News | HC Wainwright & Co. Reiterates Buy on VYNE Therapeutics, Maintains $5.75 Price Target
VYNE Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/06/2024 129.16% HC Wainwright & Co. → $5.75 Reiterates Buy → Buy 02/29/2024 129.16% HC Wainwright & Co.
No Data